A severe form of cancer, melanoma is commonly known as skin cancer. The population residing at higher altitude levels or in the close proximity to the equator, is the most susceptible to melanoma, as the symptoms are prominently initiated post-exposure to UV radiation that results in blistering sunburns. If diagnosed early in stage 0, melanoma can be surgically cured to almost 100%; however, when the disease metastizes in a body, it becomes strenuous to treat it due to the availability of a restricted range of treatment options. The selection of treatment line or systemic drug therapy entirely depends on the stage of melanoma.
Metastatic melanoma is the most severe stage (IV) of skin cancer that occurs when melanoma penetrates the skin deeper to reach various parts of a body, predominantly the subcutaneous tissue layer under the skin, lungs, bones, liver, brain, and lymph nodes. In the most severe case of metastasis, the gastrointestinal tract, adrenal glands, spleen, and heart can also be affected. Currently, only a limited set of therapies are available to promisingly treat burgeoning cases of metastatic melanoma patients. The disease thus requires more efficient and effective treatment options.
The prevalence of skin cancer in rising since the past few years (American Academy of Dermatology), which prompts at the growing demand for treatment options. The global metastatic melanoma market is driven by proven diagnostics and therapeutics, and has positive prospects following the ongoing research findings to treat the disease and extend patients’ life span. Technological developments and improving sophistication in healthcare facilities worldwide is a major factor supporting the market growth. Government initiatives related to early diagnosis and treatment awareness are playing a key role in pushing the metastatic melanoma market. Growing penetration of premium drug products and emergence of effective immune-therapies are also boosting the market further.
Metastatic Melanoma Market Trends
A new class of therapies is currently trending in the metastatic melanoma market, including targeted chemotherapy, targeted immunotherapy, targeted MAP-kinase therapy, anti-angiogenesis, and vaccines. While these therapeutic options individually aim to prolong patient life and maximize benefit, clinical trials are persisting in order to discover their combined benefits. Moreover, several new drugs and therapies are being invented and introduced to the market. In the near future, metastatic melanoma market may witness significant innovations in therapeutics, with a strong possibility of discovering customized therapy options.
For the stage IV melanoma, the U.S. FDA had approved only two drugs, including Dacarbazine (DTIC) and high-dose interleukin-2 (IL-2). However, both of these drugs have a range of side effects, and record successful treatment only in a negligible patient population. The market clearly needs a more effective class of treatments targeted to extended patient life span, substantial tumor shrinkage, and improved overall survival rate.
The recently approved drugs - BMY’s Yervoy (Ipilimumab) and Zelboraf (Vemurafenib) have entered the market with a promising outcome. The antitumor effects associated with these drugs are also being explored by researchers. Drugs such as Ipilimumab, Imatinib, and PLX4032 can be used in combination with a suitable therapy may result in an effective treatment for metastatic melanoma. In addition to drugs, several vaccines are trialled as well. The market may witness a new force of promising therapeutics in the near future.
Metastatic Melanoma Market: Region-wise Analysis
As per the regional analysis, the global market for metastatic melanoma is more pronounced in North America - especially in the U.S., as melanoma is one of the top cancer types affecting cancer patients in the U.S. The treatment rate is relatively higher as well. Europe is also a significant market, owing to rapid premium drugs invasion and increasing treatment rate. Asia Pacific is gradually emerging as a sizeable market for metastatic melanoma diagnostics and therapeutics.
Some of the key players in the global metastatic melanoma market are Abbott Diagnostics, Roche, GlaxoSmithKline, Agilent Technologies, Novartis, Merck, Sanofi, Pfizer, and Bristol-Myer Squibb.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.